Know Cancer

forgot password

A Phase I/II Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer

Phase 1/Phase 2
18 Years
Open (Enrolling)

Thank you

Trial Information

A Phase I/II Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer

The F16SIP antibody is a fully human antibody, capable of preferential localization around
tumour blood vessels while sparing normal tissues. The formation of new blood vessels is a
rare event in the adult (exception made for the female reproductive cycle), but is a
pathological feature of most aggressive types of cancer. The study aims at determining the
therapeutic potential of the F16 antibody in SIP format,labelled with the radionuclide 131I,
for the treatment of patients with different cancer types.

Inclusion Criteria:

1. Phase I:

Patients with cancer, with progressive disease in pre-study period, refractory to
conventional standard treatments.

Solid Tumor: Histologically/cytologically confirmed diagnosis of cancer, preferably
lung cancer, prostate cancer or colorectal cancer (CRC). At least one measurable
(minimum 2.0 cm), non irradiated lesion defined according to modified RECIST criteria
i.e. whenever the measurable disease is restricted to a solitary lesion, its
neoplastic nature need not be confirmed by cytology/histology.

Lymphoproliferative Diseases: Histologically/cytologically confirmed diagnosis of
lymphoproliferative disease. At least one measurable (minimum 2.0 cm) non irradiated
lesion defined according to modified RECIST criteria, i.e. whenever the measurable
disease is restricted to a solitary lesion; its neoplastic nature needs to be
confirmed by cytology/histology.

Phase II:

Patients with lymphoma, breast cancer or lung cancer with progressive disease in
pre-study period, refractory to conventional standard treatments, will be enrolled in
the study. Presence of brain metastases at time of screening does not represent an
exclusion criterion. Lesions will be evaluated according to RECIST for solid tumors
or to the Revised response criteria for malignant lymphoma (Cheson BD, JCO 2007, 25,
579-58) for lymphomas.

2. ECOG performance status grade 0 or 1.

3. Age ≥18.

4. Adequate haematological, liver and renal function (haemoglobin ≥ 9 g/dL, absolute
neutrophil count (ANC) ≥ 1.50 x 109/L; platelets ≥ 100 x 109/L, bilirubin within UNL;
alkaline phosphatase≤ 2.5 x UNL; ALT, AST ≤ UNL or ≤ 2.5 x UNL in case of liver
metastases; albumin ≥ 2.5 g/dL; creatinine ≤ UNL.

5. All acute toxic effects (excluding alopecia) of any prior therapy (including surgery
radiation therapy, chemotherapy) must have resolved to National Cancer Institute
(NCI) Common Terminology Criteria for Adverse Events (CTCAE v.3.0) Grade ≤ 1.

6. Negative serum pregnancy test for females of childbearing potential within 14 days of
starting treatment.

7. If of childbearing potential, agreement to use adequate contraceptive methods (e.g.,
oral contraceptives, condoms, or other adequate barrier controls, intrauterine
contraceptive devices, or sterilization) beginning at the screening visit and
continuing until 3 months following last treatment with study drug.

8. Evidence of a personally signed and dated IEC-approved Informed Consent indicating
that the patient (or legally acceptable representative) has been informed of all
pertinent aspects of the study.

9. Willingness and ability to comply with the scheduled visits, treatment plan,
laboratory tests and other study procedures.

10. Life expectancy of at least 3 months.

11. Signed and dated informed consent.

Exclusion Criteria:

1. Chemotherapy, radiation, hormonotherapy or immunotherapy or participation in any
investigational drug study within 4 weeks of RIT treatment at the RD (6 weeks in case
of prior nitroureas chemotherapy).

2. Prior radiation dose > 30% of bone marrow volume.

3. Presence of cirrhosis or active hepatitis.

4. Presence of serious cardiac (congestive heart failure, heart insufficiency > grade II
NYHA, angina pectoris, myocardial infarction within one year prior to study entry,
uncontrolled hypertension or arrhythmia), neurological or psychiatric disorders.

5. Presence of uncontrolled intercurrent illness or any condition which in the judgement
of the investigator would place the subject at undue risk or interfere with the
results of the study.

6. Recovery from major trauma including surgery within 4 weeks of administration of
study treatment.

7. Pregnancy or lactation or unwillingness to use adequate method of birth control.

8. Active infection or incomplete wound healing.

9. Known history of allergy to intravenously administered proteins / peptides /

10. Any conditions that in the opinion of the investigator could hamper compliance with
the study protocol.

Type of Study:


Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Phase I: Maximum tolerated Dose

Outcome Description:

Establishment of the maximum tolerated dose (MTD), a recommended dose (RD) for the phase II part, and the safety of dosimetric and therapeutic administration of escalating dosages of the human radiolabeled antibody 131I-F16SIP.

Outcome Time Frame:

4 weeks

Safety Issue:


Principal Investigator

Maddalena Sansovini, Dr

Investigator Role:

Principal Investigator

Investigator Affiliation:



Italy: National Institut of Health (Istituto Superiore di Sanità)

Study ID:




Start Date:

September 2008

Completion Date:

February 2012

Related Keywords:

  • Cancer
  • I131
  • F16
  • antibody
  • monoclonal
  • tumor targeting
  • radioimmunotherapy
  • lymphoma, breast and lung cancer
  • Patients with different cancer types